Janux Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	213.62	20.02	52.24	36.4	7.81	0.66
Short-Term Investments	438.96	324.82	275.59	339.38	0	0
Cash & Cash Equivalents	652.58	344.84	327.83	375.78	7.81	0.66
Cash Growth	105.41%	5.19%	-12.76%	4709.69%	1087.39%	-
Receivables	0.52	0	0	0	8	0
Other Current Assets	5.57	4.4	4.61	1.24	0.25	0
Total Current Assets	658.67	349.24	332.44	377.02	16.06	0.66
Property, Plant & Equipment	26.98	27.84	29.37	1.6	0.16	0.02
Other Long-Term Assets	3.34	3.33	2.21	1.21	0	0
Total Long-Term Assets	30.32	31.17	31.57	2.81	0.16	0.02
Total Assets	688.98	380.41	364.01	379.82	16.22	0.68
Accounts Payable	2.25	2.42	2.16	2.46	0.43	0.27
Deferred Revenue	0.97	1.71	7.63	5.86	8	0
Current Debt	1.57	1.52	0.76	0.19	0	4
Other Current Liabilities	5.81	7.39	5.96	4.28	-5.25	0.36
Total Current Liabilities	10.61	13.03	16.51	12.8	3.18	4.63
Long-Term Debt	22.61	23.03	24.54	0	0	0
Other Long-Term Liabilities	0	0	2.22	0.7	6.05	0
Total Long-Term Liabilities	22.61	23.03	26.76	0.7	6.05	0
Total Liabilities	33.22	36.06	43.27	13.5	9.23	4.63
Total Debt	24.19	24.54	25.31	0.19	0	4
Debt Growth	-5.31%	-3.02%	12943.81%	-	-	-
Retained Earnings	-183.52	-168.76	-110.47	-47.41	-14.74	-7.96
Comprehensive Income	-0.52	0.67	-1.54	-0.27	0	0
Shareholders' Equity	655.76	344.35	320.74	366.33	-14.64	-7.94
Net Cash / Debt	628.39	320.3	302.53	375.59	7.81	-3.34
Net Cash / Debt Growth	115.09%	5.88%	-19.45%	4707.21%	-	-
Net Cash Per Share	12.81	7.28	7.30	15.96	8.54	-4.99
Working Capital	648.06	336.21	315.93	364.22	12.88	-3.97
Book Value Per Share	13.37	7.82	7.73	15.57	-15.99	-11.87

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).